Novo Nordisk (NVO) said it expanded patient access to Wegovy through a new collaboration with WeightWatchers, beginning July 1. WeightWatchers will work with CenterWell Pharmacy as the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare Pharmacy. “By extending access to Wegovy through their integrated support system, WeightWatchers aims to provide patients with a more streamlined experience, along with convenient access to FDA-approved medication with the lifestyle support shown to improve outcomes,” the company said. Starting on July 1, Novo Nordisk is also introducing a new cash-offer price of $299 available through July 31. This $299 introductory price is available for self-paying patients who are new to the Wegovy savings offer or those who have not previously filled a prescription through NovoCare Pharmacy. This builds on the previous $199 Wegovy cash-offer patient price that expires on June 30, Novo added. Patients who redeemed the $199 Wegovy savings offer between May 22 and June 30, will be eligible for the $299 price on one fill between July 1 and July 31. For subsequent months, self-paying patients will pay $499 per month.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Is the Hims & Hers Stock (HIMS) Crash a Hidden Buying Opportunity?
- Citi sees tiered orforglipron pricing $15B opportunity for Eli Lilly
- Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks
- California seeks to cut Medicaid coverage for weight loss drugs, Bloomberg says
- Hims & Hers litigation risk ‘back on the table’, says Truist